SPI-62 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 75 | クッシング病 | 3 |
75. クッシング病
臨床試験数 : 205 / 薬物数 : 176 - (DrugBank : 45) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-006184-19-BG (EUCTR) | 22/06/2022 | 31/05/2022 | Study of SPI-62 in Patients with Adrenocorticotropic Hormone-dependent Cushing’s Syndrome | SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing’s Syndrome | Cushing’s Syndrome MedDRA version: 20.1;Level: PT;Classification code 10035109;Term: Pituitary-dependent Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: SPI-62 Product Code: SPI-62 INN or Proposed INN: Not applicable Other descriptive name: 11-ß-hydroxysteroid dehydrogenase type 1 | Sparrow Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 26 | Phase 2 | United States;Romania;Bulgaria | ||
| 2 | NCT05436639 (ClinicalTrials.gov) | June 9, 2022 | 23/6/2022 | SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor | SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor | Autonomous Cortisol Secretion (ACS);ACTH-Independent Cushing Syndrome;ACTH-Independent Adrenal Cushing Syndrome, Somatic | Drug: SPI-62 dose1;Drug: SPI-62 dose 2;Drug: SPI-62 dose 3;Drug: SPI-62 dose 4;Drug: Placebo | Sparrow Pharmaceuticals | NULL | Recruiting | 18 Years | N/A | All | 150 | Phase 2 | United States;Bulgaria;France;Romania;United Kingdom;Germany;Italy |
| 3 | NCT05307328 (ClinicalTrials.gov) | March 1, 2022 | 23/3/2022 | SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome | SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome | Cushing's Syndrome I;Cushing Disease Due to Increased ACTH Secretion;Cortisol Excess;Cortisol; Hypersecretion;Cortisol Overproduction;Ectopic ACTH Secretion | Drug: SPI-62;Drug: Placebo | Sparrow Pharmaceuticals | NULL | Recruiting | 18 Years | N/A | All | 26 | Phase 2 | Romania;Bulgaria;United States |